ABCELLERA BIOLOGICS INC.

ABCELLERA

antibodies for medical and medical laboratory use, namely, protein molecules in the form of antibodies, including full length immunoglobulin molecules, engineered immunoglobulins, and other proteins that are comprised of fragments of immunoglobulins, for medical and medical laboratory purposes;antibodies for scientific and research use, namely, protein molecules in the form of antibodies, including full length immunoglobulin molecules, engineered immunoglobulins, and other proteins that are comprised of fragments of immunoglobulins, for research and scientific purposes;research, development and consultation services in the fields of biotechnology, immunology, pharmaceuticals, and antibodies; biotechnology services, namely, providing screening and analysis of immune repertoires, analysis of natural immune responses, and discovery and development of antibodies and immune therapies;

CELIUM

downloadable software for the visualization, analysis, and manipulation of data related to antibodies;providing on-line non-downloadable software for the visualization, analysis, and manipulation of data related to antibodies;

ORTHOMAB

Therapeutic pharmaceuticals in the nature of biological and biochemical preparations, namely, antibodies, antibody derivatives and binding proteins for treatment of diseases, namely, cardiovascular, endocrinological, metabolic, musculoskeletal, neurological, and respiratory diseases, cancer, genetic rare diseases, autoimmune diseases and immunological conditions;Biological and biochemical preparations, namely, antibodies, antibody derivatives and binding proteins for research and development purposes; biochemicals, namely, bispecific antibodies for medical and scientific research; biochemicals, namely, bispecific antibodies for in vitro scientific and research use;Research and development services in the field of antibodies;